Fatigue after ischemic stroke: association with pituitary dysfunction

Pituitary dysfunction in association with fatigue after ischemic stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27430

Enrollment

118

Registered

2015-07-24

Start date

2015-10-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke fatigue pituitary dysfunction

Interventions

Besides standard treatment at enrolment, patients will undergo a general physical examination, a questionnaire, a cognitive performance test, a polygraph, a standardized fasting blood test and a routi

Eligibility

Inclusion criteria

Inclusion criteria: A subject must meet all of the following criteria: - 18 years or older; - NIHSS score12 of ¡Ý 2; - be expected to be discharged to a rehabilitation unit or to home.

Exclusion criteria

Exclusion criteria: Patients will be excluded when they: - are being treated with chemotherapeutics; - are receiving (oral or intravenous) corticosteroid therapy for more than 1 month (not: inhalation corticosteroids); - are pregnant; - are not able to complete a questionnaire due to severe aphasia, non-Dutch speaking or severe cognitive disturbances; - have a history of hypothalamic/pituitary disease that significantly affects the study results, e.g. Cushing¡¯s disease, cranial irradiation or another significant intracranial lesion, multiple sclerosis, chronic fatigue syndrome and/or psychiatric condition that interferes with interpretation of the study.

Design outcomes

Primary

Measure	Time frame
To assess the difference in prevalence of pituitary dysfunction between patients with and patients without fatigue after ischemic stroke.	—

Secondary

Measure	Time frame
1. To assess the time course of pituitary dysfunction after ischemic stroke. 2. To assess predictors of pituitary dysfunction after ischemic stroke, including stroke severity, stroke location and demographic factors. 3. To assess the association between pituitary dysfunction and depression, cognitive performance and functional status after ischemic stroke. 4. To assess independent predictors for poststroke fatigue, including pituitary dysfunction, depression, use of medication, comorbidity, laboratory disturbances, pain, illness representation, stroke location, stroke severity and sleep apnoea disorder. 5. To assess the association between fatigue and functional status after ischemic stroke.	—

Measure

Time frame

1. To assess the time course of pituitary dysfunction after ischemic stroke. 2. To assess predictors of pituitary dysfunction after ischemic stroke, including stroke severity, stroke location and demographic factors. 3. To assess the association between pituitary dysfunction and depression, cognitive performance and functional status after ischemic stroke. 4. To assess independent predictors for poststroke fatigue, including pituitary dysfunction, depression, use of medication, comorbidity, laboratory disturbances, pain, illness representation, stroke location, stroke severity and sleep apnoea disorder. 5. To assess the association between fatigue and functional status after ischemic stroke.

—

Contacts

Public ContactA. Beishuizen

VU Medical Center Department of Intensive Care P.O. Box 7057

beishuizen@vumc.nl+31(0)20 444444492

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)